Idiopathic Pulmonary Fibrosis Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Idiopathic Pulmonary Fibrosis Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight’s “Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock detailed insights into the Idiopathic Pulmonary Fibrosis Market by downloading the comprehensive report from DelveInsight @ Idiopathic Pulmonary Fibrosis Treatment Market Size
Key Takeaways from the Idiopathic Pulmonary Fibrosis Market Report
- In September 2024:- Pilant Therapeutics Inc.- A Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy and Safety of Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis (BEACON-IPF). The study will consist of an up to 35-day Screening Period, a 52-week Treatment Period, and a 14 day Safety Follow-up Period. Of note, participants who are not taking background therapy at study entry will be allowed to initiate it at any time during the study.
- In September 2024:- Boehringer Ingelheim- This study is open to adults 40 years or older with idiopathic pulmonary fibrosis (IPF). People can join the study if they are not on any treatment for IPF are on stable treatment for at least 3 months before starting the study. The purpose of this study is to find out whether a medicine called BI 1819479 helps people with IPF. 3 different doses of BI 1819479 are tested in this study.
- In September 2024:- Syndax Pharmaceuticals- A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects With Idiopathic Pulmonary Fibrosis (IPF). The study will evaluate the efficacy and safety of axatilimab in participants with IPF.
- It is estimated that the Idiopathic Pulmonary Fibrosis treatment market will experience significant changes during the forecast period of 2024–2034, owing to the launch of new therapies that are in clinical development.
- As per DelveInsight analysis in 2023, there were nearly 192 thousand cases of diagnosed prevalent cases of IPF in the 7MM. Among which the US accounted for the highest around 94 thousand cases alone. These cases are anticipated to follow the same trend and rise gradually throughout the 2024–2034 period.
- DelveInsight’s analysis shows that males had a higher prevalence of diagnosed IPF cases than females in 2023. In the US, approximately 53 thousand males and 41 thousand females were affected by the disease. These figures suggest a significant gender disparity in the prevalence of idiopathic pulmonary fibrosis.
- DelveInsight’s 2023 analysis in Japan segmented IPF cases by age, revealing the highest prevalence in the 80+ age group, with nearly 26 thousand cases.
- In 2023, the EU4 and the UK had nearly 78 thousand diagnosed prevalent cases of IPF, with Germany accounting for the highest number of cases in the region.
- Our secondary analysis found that in 2023, the EU4 and the UK reported approximately 39 thousand diagnosed cases of moderate IPF, while only about 16 thousand cases were classified as severe IPF.
- The leading Idiopathic Pulmonary Fibrosis Companies such as FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, LLCs, MediciNova, PureTech, Bristol-Myers Squibb, Nitto Denko Corporation, Vicore Pharma AB and others.
- Promising Idiopathic Pulmonary Fibrosis Therapies such as Pirfenidone, Deupirfenidone, SC1011, TTI-101, PLN-74809, and others.
Gain a competitive edge in the Idiopathic Pulmonary Fibrosis Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Idiopathic Pulmonary Fibrosis Treatment Drugs
Idiopathic Pulmonary Fibrosis Epidemiology Segmentation in the 7MM
- Total Idiopathic Pulmonary Fibrosis Diagnosed Prevalent Cases
- Idiopathic Pulmonary Fibrosis Gender-specific Diagnosed Prevalent Cases
- Idiopathic Pulmonary Fibrosis Age-specific Diagnosed Prevalent Cases
- Idiopathic Pulmonary Fibrosis Severity-specific Diagnosed Prevalent Cases
Idiopathic Pulmonary Fibrosis Market Insights
IPF is characterized by lung scarring, which progressively impairs breathing. It is believed that damage to the alveolar epithelium and abnormal wound healing play significant roles in the disease’s progression. The treatment of IPF encompasses both pharmacological and non-pharmacological strategies aimed at managing symptoms and slowing disease progression. “At present, two medications are authorized for managing IPF: OFEV and ESBRIET. These agents, classified as anti-fibrotics, have demonstrated efficacy in clinical trials by decelerating lung fibrosis or scarring. Pirfenidone, a modified pyridine compound, possesses properties that are anti-fibrotic, anti-inflammatory, and antioxidant, contributing to its therapeutic effects in IPF.”
Discover key developments and opportunities in the Idiopathic Pulmonary Fibrosis Market. Click here to learn more from DelveInsight’s latest report @ Idiopathic Pulmonary Fibrosis Market Size
Idiopathic Pulmonary Fibrosis Emerging Therapies Profile
- BI 1015550: Boehringer Ingelheim
- Tyvaso (treprostinil): United Therapeutics
- Garadacimab: CSL Behring
Idiopathic Pulmonary Fibrosis Marketed Drugs
- OFEV (Nintedanib): Boehringer Ingelheim Pharma GmbH
Idiopathic Pulmonary Fibrosis Market Outlook
There are two antifibrotic agents approved for use in idiopathic pulmonary fibrosis. These are Pirfenidone and Nintedanib (tyrosine kinase inhibitors). Both drugs are known to slow the disease progression but not significantly impact mortality. For this reason, early initiation of therapy is recommended. Further studies have also decreased exacerbations of idiopathic pulmonary fibrosis with these drugs. Serial monitoring of liver function tests is recommended while on either drug. The most common side effect reported with Nintedanib is diarrhea and pirfenidone rash, photosensitivity, and gastrointestinal discomfort.
Download DelveInsight’s Idiopathic Pulmonary Fibrosis Market report today and stay ahead in this rapidly evolving field. @ Idiopathic Pulmonary Fibrosis Clinical Trials
Scope of the Idiopathic Pulmonary Fibrosis Market Report
- Coverage- 7MM
- Idiopathic Pulmonary Fibrosis Companies- FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, LLCs, MediciNova, PureTech, Bristol-Myers Squibb, Nitto Denko Corporation, Vicore Pharma AB and others.
- Idiopathic Pulmonary Fibrosis Therapies- Pirfenidone, Deupirfenidone, SC1011, TTI-101, PLN-74809, and others.
- Idiopathic Pulmonary Fibrosis Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Idiopathic Pulmonary Fibrosis Unmet Needs, KOL’s views, Analyst’s views, Idiopathic Pulmonary Fibrosis Market Access and Reimbursement
Download the report to understand which factors are driving Idiopathic Pulmonary Fibrosis Market Trends @ Idiopathic Pulmonary Fibrosis Market Trends
Table of Content
1 Key Insights
2 Report Introduction
3 Idiopathic Pulmonary Fibrosis (IPF) Market Overview at a Glance
4 Epidemiology and Market Forecast Methodology
5 Key Events
6 Executive Summary of Idiopathic Pulmonary Fibrosis (IPF)
7 Disease Background and Overview of IPF
8 Epidemiology and Patient Population of IPF
9 Patient Journey
10 Marketed Drugs
11 Emerging Drugs
12 IPF: Seven Major Market Analysis
13 KOL Views
14 SWOT Analysis
15 Unmet needs
16 Market Access and Reimbursement
17 Appendix
18 Report Methodology
19 DelveInsight Capabilities
20 Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Idiopathic Pulmonary Fibrosis Treatment Market Size in the 7MM was ~USD 3,300 million in 2023, estimated DelveInsight